Sandra Dabora, M.D., Ph.D.
Selected Papers
Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto AA, Chung J, Choy YS, Reeve MP, Thiele E, Egelhoff JC, Kasprzyk-Obara J, Domanska-Pakiela D, Kwiatkowski DJ. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2 compared with TSC1 disease in multiple organs. American Journal of Human Genetics. 2001; 68:64-80. 
Franz DN, Brody A, Meyer C, Leonard J, Chuck G, Dabora S, Sethurman G, Colby TV, Kwiatkowski DJ, McCormack FX. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. American J Respir Crit Care Med. 2001;164:661-668.
Dabora SL, Roberts PR, Nieto A, Perez R, Jozwiak S, Franz DN, Thiele EA, Sims K, Kwiatkowski DJ. Association of a high expressing interferon-g allele with a lower frequency of kidney angiomyolipomas in TSC2 patients. American Journal of Human Genetics. 2002;71;750-758.
Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V, Sun Y Schwartz K, El Hashemite N, Lader A, Onda H, Zhang H, Kwiatkowski DJ, Dabora SL. Efficacy of a rapamycin analog (CCI-779) and IFN-g in tuberous sclerosis mouse models. Genes, Chromosomes and Cancer; 2005;42:213-227.
Lee L, Sudentas P, Dabora SL. Combination of a rapamycin analog (CCI-779) plus interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex. Genes, Chromosomes and Cancer, 2006;45:933-944.
Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D, Stanbridge E, Atkins M. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clinical Genitourinary Cancer, 2007; 5:379-385.
Messina Messina MP, Rauktys A, Lee L, and Dabora SL. Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779. BMC Pharmacology, 2007; 7:14.
Rauktys A, Lee N, Lee L, and Dabora SL. Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model. BMC Dermatology, 2008; 8:1.
